All Stories

  1. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis
  2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis
  3. Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis
  4. Psoriasis-Associated Itch: Etiology, Assessment, Impact, and Management
  5. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment
  6. YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis
  7. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States
  8. Psoriasis-Associated Cutaneous Pain: Etiology, Assessment, Impact, and Management
  9. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting
  10. Drug survival of secukinumab for moderate-to-severe plaque psoriasis
  11. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis
  12. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review
  13. Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review
  14. Dosage adjustments in patients with psoriasis on adalimumab - a retrospective chart review
  15. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice
  16. Treating Psoriasis in patients who have solid organ transplants
  17. Review of U.S. registries for psoriasis
  18. Risk of aortic aneurysm in patients with psoriasis: a retrospective cohort study
  19. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression
  20. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide
  21. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis
  22. Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
  23. Adalimumab use in patients with psoriasis and hepatitis B: a case series
  24. Atopic dermatitis 2017: where we were 10–15 years ago in psoriasis
  25. A reply to: ‘Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials'
  26. Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council
  27. Letter regarding Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
  28. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics
  29. Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis
  30. Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
  31. An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship
  32. Photodynamic therapy for psoriasis
  33. The risk of deep fungal infections during biologic therapy for psoriasis
  34. Moderate to Severe Psoriasis
  35. Mild to Moderate Psoriasis
  36. Pediatric Psoriasis
  37. Adalimumab
  38. Mild to Moderate Psoriasis to Severe Psoriasis
  39. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
  40. Tumor Necrosis Factor Inhibitors and Myocardial Infarction in Psoriasis
  41. Psoriasis Flare from Koebner's Phenomenon after Acupuncture
  42. A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis
  43. Localized Contact Urticaria Caused by Lidocaine/Tetracaine Peel
  44. Erythematous Papules and Pustules on the Scalp
  45. The Nikolskiy Sign
  46. Bluish Subcutaneous Nodule in a Child—Quiz Case
  47. Calcinosis Cutis of Juvenile Dermatomyositis Treated with Incision and Drainage
  48. Academic Dermatology
  49. A Unique Pattern of Hyperhidrosis and Herpes Zoster
  50. Postherpetic Poliosis
  51. Issues for travelers
  52. Tropical manifestations of common viral infections
  53. Rickettsial infections
  54. Varicella-Zoster Virus
  55. Varicella-Zoster Virus